Securities code: Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) securities abbreviation: Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) Announcement No.: 2022013
Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864)
Announcement on abnormal fluctuations in the company’s stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Abnormal fluctuation of stock trading
Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) (hereinafter referred to as “the company”) the stock trading price rose by 20% from the closing price for three consecutive trading days on March 16, March 17 and March 18, 2022. According to the trading rules of Shenzhen Stock Exchange and other relevant regulations, it belongs to the situation of abnormal fluctuation of stock trading.
2、 The company pays attention to and verifies relevant information
1. Through self-examination, the information disclosed by the company in the early stage does not need to be corrected or supplemented.
2. The company’s operation and internal and external business environment have not changed significantly recently.
3. After verification, the company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
4. The company, the controlling shareholder and the actual controller have no major events that should be disclosed or not disclosed about the company, or major events in the planning stage.
5. The controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
6. The company does not violate the provisions on fair information disclosure.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions, and information that has a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. The company disclosed the 2021 annual performance forecast (Announcement No.: 2022001) on January 18, 2022. As of the disclosure date of this announcement, the above performance is not expected to be corrected. The specific financial data of the company in 2021 shall be subject to the annual report of the company in 2021. The undisclosed regular performance information of the company is not provided to any third party other than the accounting firm audited by the company.
3. The company solemnly reminds investors: China Securities News, Securities Daily, securities times, Shanghai Securities News and cninfo（ http://www.cn.info.com.cn. ）As the information disclosure media designated by the company, all information of the company shall be subject to the information published in the above designated media. Please invest rationally and pay attention to risks.
Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) board of directors
March 18, 2022
